Logo

CERT

Certara, Inc.

CERT

Certara, Inc. • NASDAQ
$9.16 ▲ 0.22% (+0.02)
Market Cap $1.47 B
52w High $15.69
52w Low $8.03
Dividend Yield 0%
P/E 130.86
Volume 584.51K
Outstanding Shares 160.82M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $104.616M ▲ $44.08M ▼ $1.525M ▲ 1.458% ▲ $0.01 ▲ $23.37M ▼
Q2-2025 $104.57M ▼ $54.302M ▼ $-1.968M ▼ -1.882% ▼ $-0.012 ▼ $29.871M ▲
Q1-2025 $106.004M ▲ $56.86M ▲ $4.743M ▼ 4.474% ▼ $0.03 ▼ $27.962M ▲
Q4-2024 $100.361M ▲ $56.095M ▲ $6.577M ▲ 6.553% ▲ $0.041 ▲ $25.4M ▲
Q3-2024 $94.82M $55.037M $-1.371M -1.446% $-0.009 $-6.409M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $172.711M ▲ $1.536B ▼ $471.049M ▼ $1.065B ▼
Q2-2025 $162.266M ▼ $1.543B ▼ $472.867M ▼ $1.071B ▼
Q1-2025 $179.086M ▼ $1.561B ▼ $476.732M ▼ $1.084B ▲
Q4-2024 $179.183M ▼ $1.575B ▲ $516.448M ▲ $1.059B ▲
Q3-2024 $233.023M $1.543B $489.824M $1.053B

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $1.525M ▲ $32.314M ▲ $-6.792M ▲ $-14.483M ▲ $10.445M ▲ $32.093M ▲
Q2-2025 $-1.968M ▼ $17.842M ▲ $-6.961M ▼ $-30.694M ▼ $-16.82M ▼ $17.906M ▲
Q1-2025 $4.743M ▼ $17.352M ▼ $-5.774M ▲ $-13.996M ▼ $-97K ▲ $11.578M ▼
Q4-2024 $6.577M ▲ $49.369M ▲ $-97.163M ▼ $-1.303M ▲ $-53.84M ▼ $43.533M ▲
Q3-2024 $-1.371M $16.987M $-5.508M $-5.605M $8.424M $16.823M

Revenue by Products

Product Q1-2025Q2-2025Q3-2025
Reportable Segment
Reportable Segment
 $110.00M ▲$100.00M ▼$100.00M ▲

Five-Year Company Overview

Income Statement

Income Statement Revenue has grown steadily over the past several years, and gross profit has risen alongside it, suggesting the core business is gaining scale. However, profitability has been uneven. Operating results have bounced between small profits, break‑even, and modest losses, and net income has mostly hovered around slightly negative territory with one clearly profitable year in the middle. This pattern points to a company still balancing growth investments, integration costs, and operating efficiency. Overall, the top line looks healthy, but the bottom line has yet to show consistent, durable profitability.

Balance Sheet

Balance Sheet The balance sheet looks relatively solid and stable. Total assets and shareholder equity have trended upward over time, which signals ongoing reinvestment in the business and limited erosion of the capital base. Debt levels have stayed fairly steady and appear moderate compared with the size of the company and its equity, implying manageable leverage. Cash balances move around year to year but remain meaningful, giving the company flexibility to fund operations, invest, or service its obligations without appearing stretched.

Cash Flow

Cash Flow Cash generation is a clear bright spot. Operating cash flow has been consistently positive and gradually improving, even in years when reported earnings were weak or negative. Free cash flow has also remained positive, helped by relatively low capital spending needs, which is typical of a software‑ and services‑heavy model. This combination suggests the accounting losses reflect non‑cash items and investment choices more than underlying business weakness, and that the company can largely fund its growth and debt commitments from its own cash generation.

Competitive Edge

Competitive Edge Certara occupies a specialized and influential niche at the intersection of drug development and advanced modeling. Its biosimulation platforms are widely used, deeply embedded in customer workflows, and recognized by major regulators, which creates trust and high switching costs. The blend of software and expert consulting makes it harder for pure software or pure services competitors to displace. At the same time, the company is exposed to trends in pharma and biotech R&D spending, and it faces a dynamic competitive landscape as large technology firms, specialized software vendors, and pharma companies’ internal teams all push into AI‑driven modeling and analytics.

Innovation and R&D

Innovation and R&D Innovation is a core strength. Certara is a leader in biosimulation and model‑informed drug development, anchored by flagship platforms like Simcyp and Phoenix, and complemented by tools such as Pinnacle 21 and the Chemaxon capabilities. The company is actively layering in cloud delivery and artificial intelligence through offerings like Certara.AI, Phoenix Cloud, and AI‑enhanced regulatory writing and modeling tools. Its large team of scientists and close work with regulators reinforce its ability to set and maintain standards in this space. The key execution risks are keeping pace with rapid AI and cloud developments, integrating acquisitions smoothly, and ensuring its platforms remain the default choice as the technology frontier moves.

Summary

Certara combines steady revenue growth and strong cash generation with a solid balance sheet and a defensible position in a specialized, high‑value corner of healthcare technology. The company’s tools are deeply trusted by both drug developers and regulators, and its integration of software, services, and scientific expertise gives it a meaningful moat. However, accounting profitability has been inconsistent, reflecting ongoing investment and cost structure challenges, and the environment around AI‑driven drug development is becoming more competitive. Going forward, the main things to watch are the company’s ability to translate its scientific and regulatory advantages into more consistent margins, to successfully scale its cloud and AI offerings, and to maintain its leadership as the broader ecosystem of pharma, biotech, and tech players evolves.

NEWS

November 6, 2025 · 4:15 PM UTC

Certara Reports Third Quarter 2025 Financial Results

Read more

November 4, 2025 · 8:00 AM UTC

Certara Automates Scientific Workflows with Phoenix® Cloud

Read more

October 31, 2025 · 8:00 AM UTC

Certara to Participate in Upcoming Investor Conferences

Read more

October 30, 2025 · 4:15 PM UTC

Certara Expands Biosimulation Market with AI-Driven QSP Platform

Read more

October 20, 2025 · 8:00 AM UTC

Certara Scientists are Among the Topmost Cited Biopharma Researchers

Read more